Navigation Links
Generex to Increase Patient Enrollment of its Phase II Breast Cancer Vaccine Study
Date:1/25/2011

ed interim data from the study indicating fewer relapses in the AE37 arm of the study versus the placebo controlled arm.  The Company anticipates that a Phase III clinical study of the breast cancer vaccine will be initiated prior to the completion of the extant Phase II study.  Results from the ongoing Phase II study would be used for patient number adjustment, thereby assuring statistical significance in the Phase III registration trial.

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies.  Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs).  The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device.  The Company's buccal insulin spray product, Generex Oral-lyn™ is in Phase III clinical trials at several sites around the world.  Antigen Express, Inc. is a wholly owned subsidiary of Generex.  The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases.  Antigen Express has pioneered the use of specific CD4+ T helper stimulation in immunotherapy.  One of its platform technologies relies on inhibition of expression of the Ii protein.  Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T helper cells and prevents the further growth of cancer cells.  For more information, visit the Generex website at www.generex.com or the Antigen Express website at
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Generex and RXi Pharmaceuticals Announce Positive Research Data Using RNAi Technology in the Development of Therapeutic Vaccines for Cancer
2. Generex Announces Extension of Global Medical Direct Acquisition Closing Date
3. Generex Receives New Patent for Buccal Drug Delivery Platform Technologies
4. Generex Announces Publication of New Positive Generex Oral-lyn™ Data in Peer-Reviewed Journal
5. Generex Oncology Awarded Two IRS Therapeutic Discovery Project Grants
6. Generex Common Stock Now Quoted on the Over-the-Counter Bulletin Board
7. Generex to Participate in Canadian Diabetes Association Conference
8. Generex Reschedules Live Video Webcast
9. Generex Announces Approval of Adjournment Proposal and Adjourned Special Meeting Date
10. Generex Announces That Adjournment Will be Sole Matter Considered at Reconvened Special Meeting of Stockholders on October 15, 2010
11. Generex Provides Clarification for Special Meeting Voting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014 Imprimis Pharmaceuticals, ... company dedicated to delivering high quality and novel medicines ... that Chief Executive Officer Mark Baum will ... Craig-Hallum Alpha Select Conference in New York City.  Mr. ... Go Dropless™ campaign in ophthalmology. The presentation is ...
(Date:9/16/2014)... YORK , Sept. 16, 2014  Relmada Therapeutics, ... for the treatment of chronic pain, announced today that ... Kettering Cancer Center (MSKCC) in a series of animal ... a new tamper-resistant, extended release form of levorphanol.  Gavril ... for these studies. Dr. Pasternak said, ...
(Date:9/16/2014)... , N.J. and NEW PROVIDENCE, N.J. , ... experts will present a paper on the critical elements ... oxygen storage and deliver systems at the American Society ... be held at the Chicago Sheraton Hotel and Towers ... Derrick West , program manager of Hospital ...
Breaking Medicine Technology:Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 2Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 3Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 4Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 2Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 3Linde Healthcare experts to present details on installation of medical oxygen storage and distribution systems at ASPE convention 2Linde Healthcare experts to present details on installation of medical oxygen storage and distribution systems at ASPE convention 3
(Date:9/16/2014)... Tara Haelle ... News) -- About 14.5 million U.S. cancer survivors are ... the American Association for Cancer Research reported Tuesday. ... and include nearly 380,000 survivors of childhood cancer, according ... advances in prevention, identification, research and treatment of cancer ...
(Date:9/16/2014)... New York (PRWEB) September 16, 2014 ... ) filed against C.R. Bard, Inc. continue to ... in U.S. District Court, Southern District of West ... Order dated September 15, 2014, the Court has ... beneficial to the proceeding. The Order indicates that ...
(Date:9/16/2014)... Danny Dreyer, ChiRunning & ChiWalking founder ... events throughout the U.S. Dreyer is one of the ... taught a full circuit of nationwide workshops since 2004. ... tracks at his workshops so participants of all levels ... techniques. , Workshop schedule: , ,     September ...
(Date:9/16/2014)... One in five American men admits to using ... survey shows. A nationally representative study from ... is more prevalent than diabetes. This violence includes ... hitting, kicking, biting, choking, burning or threatening their ... Although abuse by high-profile professional athletes has recently ...
(Date:9/16/2014)... The Wistar Institute,s Meenhard Herlyn, D.V.M., D.Sc., is ... Program of Research Excellence (SPORE) grant, a prestigious ... researchers at Wistar and the University of Pennsylvania ... this SPORE is to translate fundamental laboratory discoveries ... melanoma and other skin cancers. , Melanoma is ...
Breaking Medicine News(10 mins):Health News:Targeted Drugs Among Successes Against Cancer, Says New Report 2Health News:Targeted Drugs Among Successes Against Cancer, Says New Report 3Health News:Targeted Drugs Among Successes Against Cancer, Says New Report 4Health News:Vaginal Mesh Lawsuit News: Discovery Conferences Scheduled for Federal Transvaginal Mesh Lawsuits Filed Against C.R. Bard, Bernstein Liebhard LLP Reports 2Health News:Vaginal Mesh Lawsuit News: Discovery Conferences Scheduled for Federal Transvaginal Mesh Lawsuits Filed Against C.R. Bard, Bernstein Liebhard LLP Reports 3Health News:Vaginal Mesh Lawsuit News: Discovery Conferences Scheduled for Federal Transvaginal Mesh Lawsuits Filed Against C.R. Bard, Bernstein Liebhard LLP Reports 4Health News:Join ChiRunning® Founder, Danny Dreyer, on Fall 2014 US Workshop 2Health News:Join ChiRunning® Founder, Danny Dreyer, on Fall 2014 US Workshop 3Health News:1 in 5 U.S. Men Admits to Violence Against Spouse, Partner 2Health News:Wistar and Penn Medicine collaborate on $12.1 million SPORE grant in melanoma 2Health News:Wistar and Penn Medicine collaborate on $12.1 million SPORE grant in melanoma 3
... disturbing implications for the government, pension companies and life ... warning that increases in longevity translate into bad news ... look after us when we are old; to make ... uncertain. , Kevin Dowd, Professor of Financial Risk Management ...
... 29th 2007 With the genomic revolution radical improvement ... cancer. This is of the utmost importance, since the ... detection. In a special issue of Disease Markers, published ... the identification and understanding of biomarkers for epithelial ovarian ...
... found incidentally during a CT scan, and the masses ... according to a recent study conducted by researchers at ... increased utilization of CT, we are frequently encountering findings ... scanned, the so called incidentalomas, of which adrenal masses ...
... winning program at the Best Practices in Consumer ... 25-26, 2008, WASHINGTON, Nov. 29 Today ... selected the finalists for its,inaugural Best Practices in ... attracted entries detailing,innovative and proven programs that are ...
... Revolutionary new intimacy creme aids women in greater ... Passion Parties, Inc. is excited to,add the new ... cornerstone of the Passion Parties product line complete ... the G-Spot Creme instills a,positive level of confident ...
... Signs contract with Best Medical International Inc., ... leading,provider of medical isotopes and radiopharmaceuticals, today signed ... its external beam,therapy and self-contained irradiator product lines. ... growth strategy to focus its resources on being ...
Cached Medicine News:Health News:URAC Names Medco as a Finalist in First-ever Best Practices in Consumer Empowerment and Protection Awards 2Health News:URAC Names Medco as a Finalist in First-ever Best Practices in Consumer Empowerment and Protection Awards 3Health News:Passion Parties Hits the Spot 2Health News:MDS Nordion Divests Non Strategic Product Lines 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: